New promises and challenges in the treatment of advanced non-small-cell lung cancer
Cet article passe en revue les progrès réalisés pour le traitement des cancers du poumon non à petites cellules de stade avancé puis examine les défis à relever pour identifier les biomarqueurs permettant de personnaliser les traitements, lever les résistances thérapeutiques, réduire les coûts et assurer l'accessibilité aux traitements anticancéreux
Targeted therapies and immunotherapies have radically improved treatment for advanced non-small-cell lung cancer (NSCLC). Tyrosine kinase inhibitors targeting oncogenic driver mutations continue to evolve over multiple generations to enhance effectiveness and tackle drug resistance. Immune checkpoint inhibitors remain integral for the treatment of NSCLCs that do not have specific actionable genetic mutations. Antibody?drug conjugates and bispecific antibodies are being integrated into treatment guidelines, and emerging therapies include T-cell engagers, cellular therapies, cancer vaccines, and external devices. Despite these advances, challenges remain in identifying predictive biomarkers to individually tailor treatments, abrogate resistance, reduce costs, and ensure optimal cancer treatment accessibility.
The Lancet , résumé, 2023